Empowered Funds LLC Purchases 2,278 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Empowered Funds LLC lifted its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 5.4% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 44,809 shares of the company’s stock after buying an additional 2,278 shares during the quarter. Empowered Funds LLC’s holdings in Voyager Therapeutics were worth $262,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. ProShare Advisors LLC purchased a new position in shares of Voyager Therapeutics in the first quarter valued at about $101,000. Vanguard Group Inc. grew its position in shares of Voyager Therapeutics by 27.8% during the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after purchasing an additional 702,030 shares in the last quarter. American International Group Inc. raised its stake in Voyager Therapeutics by 22.9% during the 1st quarter. American International Group Inc. now owns 19,397 shares of the company’s stock valued at $181,000 after purchasing an additional 3,610 shares during the period. Lazard Asset Management LLC lifted its holdings in Voyager Therapeutics by 95.3% in the 1st quarter. Lazard Asset Management LLC now owns 18,742 shares of the company’s stock worth $174,000 after purchasing an additional 9,146 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Voyager Therapeutics by 3.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock worth $9,702,000 after purchasing an additional 37,144 shares during the period. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Stock Up 1.7 %

Shares of VYGR opened at $5.75 on Tuesday. The business has a fifty day moving average of $6.54 and a 200 day moving average of $7.38. The company has a market cap of $314.12 million, a PE ratio of 8.10 and a beta of 0.89. Voyager Therapeutics, Inc. has a 52-week low of $5.19 and a 52-week high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same period in the prior year, the company posted ($0.59) EPS. As a group, research analysts anticipate that Voyager Therapeutics, Inc. will post -1.03 earnings per share for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares of the company’s stock, valued at $500,525.82. This represents a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Wedbush decreased their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 18th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $17.00.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.